SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
SAGE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
ICPTIntercept Pharmaceuticals, Inc.
-0.02%66.8522.0%$203.98m
ZGNXZogenix, Inc.
0.25%39.7516.8%$134.32m
SHPGShire PLC Sponsored ADR
-1.74%145.250.4%$129.18m
VRXValeant Pharmaceuticals International, Inc.
-2.56%12.1614.2%$114.11m
PRGOPerrigo Co. Plc
-0.11%87.436.5%$91.26m
AERIAerie Pharmaceuticals, Inc.
0.39%65.108.6%$62.29m
CTLTCatalent Inc
0.68%42.962.7%$56.77m
MNKMallinckrodt Plc
-1.22%32.4217.7%$56.11m
JAZZJazz Pharmaceuticals Plc
-0.66%144.052.2%$51.66m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-1.62%107.637.6%$49.09m
UTHRUnited Therapeutics Corporation
1.64%121.0114.4%$45.84m
ENDPEndo International Plc
-2.03%7.728.9%$40.92m
PTLAPortola Pharmaceuticals, Inc.
0.36%50.657.9%$39.31m
HZNPHorizon Pharma plc
-0.35%14.097.6%$35.09m
MDCOMedicines Company
-1.36%33.9822.1%$32.03m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company engages in the development and commercialization of novel medicines to treat central nervous system disorders. Its product candidate includes SAGE-547, which is in clinical development for super-refractory status epileptics; SAGE-217; and SAGE-689, which are in IND-enabling toxicology and safety pharmacology testing. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.